Every material Form 8-K AbCellera Biologics Inc. has filed with the SEC since August 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
AbCellera priced an underwritten public offering of 17,435,897 common shares at $9.75 per share, plus pre-funded warrants for up to 3,076,926 shares, with closing expected on or about August 14, 2026. The company estimates net proceeds of about $187.0 million and plans to use them to fund its internal pipeline, including lead clinical program ABCL635, and for working capital. The new shares will add to the existing share count, which dilutes current shareholders' ownership.
Priced 17,435,897 common shares at $9.75 per share, and pre-funded warrants for up to 3,076,926 shares at $9.74999 each
Gross proceeds expected to be about $200.0 million; estimated net proceeds about $187.0 million after underwriting discounts, commissions and offering expenses
Proceeds to fund research, development and clinical advancement of the internal pipeline, including ABCL635, and for working capital and general corporate purposes
Closing expected on or about August 14, 2026; the company and its executive officers and directors agreed to a 60-day restriction on share sales, subject to exceptions
AbCellera reported top-line results from the Phase 2 portion of its Phase 1/2 trial of ABCL635, an investigational antibody for hot flashes due to menopause. In the 92-patient, placebo-controlled study, the single 600 mg dose reduced moderate-to-severe hot flash frequency and severity versus placebo at week 4, with no serious adverse events in the ABCL635 group. The results are four-week interim data from a small study, and the company says further data and Phase 3 planning are still ahead.
Frequency of moderate-to-severe hot flashes fell 83% from baseline at week 4 on ABCL635 versus 33% on placebo, a placebo-adjusted difference of 50%.
Severity fell 58% from baseline at week 4 on ABCL635 versus 12% on placebo, a placebo-adjusted difference of 46%.
No serious adverse events occurred in the ABCL635 group, compared with one serious adverse event in the placebo group.
Company plans to present additional data at medical conferences later this year and to complete a 12-week follow-up to support dose selection.
AbCellera said it will release top-line results from its Phase 2 trial of ABCL635, an antibody drug for moderate-to-severe vasomotor symptoms (hot flashes) due to menopause, before the market opens on Monday, August 10, 2026. The company will also hold an investor conference call and webcast that morning at 4:30 a.m. Pacific Time. The filing contains no trial results, so the announcement itself does not yet show whether the drug worked, but the data will be a key test for the program's future.
Top-line Phase 2 data for ABCL635 to be released before market open on Monday, August 10, 2026
Investor conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET the same day
Trial (NCT07118891) is randomized, double-blind and placebo-controlled with approximately 80 postmenopausal women
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AbCellera Biologics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →